SHF (SHFS) investor relations material

Executive summary

• Q3 2026 revenue rose 6.5% YoY to $1.95M; nine-month revenue increased 4.5% to $5.86M, led by higher loan program income.

• Recurring losses, operating cash use, litigation exposure and capital-structure issues leave substantial doubt about continued operations; management’s plans do not alleviate the doubt.

Financial highlights

• Q3 operating expenses fell 3.2% to $2.95M and operating loss narrowed 17.7% to $1.00M; nine-month expenses fell 1.4% to $9.65M and operating loss narrowed to $3.79M.

• Q3 net loss was $0.98M versus net income of $0.18M; nine-month net loss was $4.27M versus $1.58M. Prior-year Q3 included a $3.34M debt-extinguishment gain.

• Q3 basic and diluted loss per share was $0.95; nine-month loss per share was $8.08 versus $6.67, and loss attributable to common stockholders included $1.07M of deemed dividends.

• Nine-month operating cash use was $4.05M versus $2.35M a year earlier; investing activities provided $0.53M and financing activities provided $1.13M.

Outlook and guidance

• Priorities include maintaining client and financial-institution relationships, operational continuity, expense and liquidity management, and pursuing strategic alternatives.

• Professional services expense is expected to rise in Q4 2026 and remain elevated due to filings, the proposed transaction, potential reverse-split activity and Abaca litigation.

• Liquidity measures include cost reductions if conditions weaken and bi-weekly monitoring of a rolling 52-week cash-flow forecast; these measures do not remove substantial doubt for the next 12 months.

• The ELOC is not expected to be drawn while the Opifex term sheet is pending; completion of the transaction is not assured.